No Data
No Data
SA Asks: How Should Investors Position Portfolios Ahead of Fed Vote?
SPDR S&P Biotech ETF Options Spot-On: On December 13th, 132.6K Contracts Were Traded, With 958.89K Open Interest
On December 13th ET, $SPDR S&P Biotech ETF(XBI.US)$ had active options trading, with a total trading volume of 132.6K options for the day, of which put options accounted for 67.25% of the total
SPDR S&P Biotech ETF Options Spot-On: On December 12th, 124.48K Contracts Were Traded, With 924.94K Open Interest
On December 12th ET, $SPDR S&P Biotech ETF(XBI.US)$ had active options trading, with a total trading volume of 124.48K options for the day, of which put options accounted for 69.13% of the total
The small Kennedy effect: Major exodus of pharmaceutical stocks in the USA
Several weeks have passed since Trump nominated Alex Azar as Secretary of Health and Human Services, yet the trend of investors withdrawing from the medical care sector has not diminished. So far this year, the performance of the Health Care Select Sector SPDR Fund (XLV) in comparison to the S&P 500 index is approaching the lowest level in the past thirty years. Goldman Sachs believes that significant economic events may need to occur + related policies become clearer + corporate profit expectations are raised in order to attract investors back.
Top Quant-rated Cyclical Stocks, as Group Is Expected to Outperform in 2025
Barclays's 'Bang-for-the-buck' Tail Hedging ETFs: HYG, XLF, IYR